A phase I, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in subjects with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML)

被引：2
|
作者：
Skikne, B. S.
Ward, M. R.
Nasser, A.
Aukerman, L.
Garcia-Manero, G.
机构：
[1] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[2] Pharmion Corp, Boulder, CO USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.7091
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7091
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Skikne, Barry
    Cogle, Christopher R.
    Ning, Yuhong
    MacBeth, Kyle J.
    Laille, Eric
    Ward, M. Renee
    [J]. BLOOD, 2009, 114 (22) : 53 - 53
  • [2] The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML)
    Laille, E.
    Ward, R.
    Nasser, A.
    Stoltz, M.
    Cogle, C.
    Gore, S.
    Skikne, B. S.
    Garcia-Manero, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
  • [4] Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study
    Kirschbaum, Mark
    Gojo, Ivana
    Goldberg, Stuart L.
    Kujawski, Lisa
    Atallah, Ehab
    Marks, Peter
    Di Gravio, Donna
    Pyle, Lisa
    Rizvi, Syed
    Issa, Jean-Pierre J.
    [J]. BLOOD, 2009, 114 (22) : 824 - 825
  • [5] Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
    Bauer, Todd M.
    Besse, Benjamin
    Martinez-Marti, Alex
    Trigo, Jose Manuel
    Moreno, Victor
    Garrido, Pilar
    Ferron-Brady, Geraldine
    Wu, Yuehui
    Park, Jennifer
    Collingwood, Therese
    Kruger, Ryan G.
    Mohammad, Helai P.
    Ballas, Marc S.
    Dhar, Arindam
    Govindan, Ramaswamy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1828 - 1838
  • [6] A PHASE4, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS (PK) OF SUBCUTANEOUS (SC) AZACITIDINE IN TAIWANESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Laille, E.
    Chou, W.
    Yeh, S.
    Dong, Q.
    Songer, S.
    Beach, C.
    [J]. HAEMATOLOGICA, 2013, 98 : 577 - 578
  • [7] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Attar, Eyal C.
    Amrein, Philip C.
    Fraser, James W.
    Fathi, Amir T.
    McAfee, Steven
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Stone, Richard M.
    Foster, Julia
    Neuberg, Donna
    Ballen, Karen K.
    [J]. LEUKEMIA RESEARCH, 2013, 37 (09) : 1016 - 1020
  • [8] An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
    Savona, Michael R.
    Odenike, Olatoyosi
    Amrein, Philip C.
    Steensma, David P.
    DeZern, Amy E.
    Michaelis, Laura C.
    Faderl, Stefan
    Harb, Wael
    Kantarjian, Hagop
    Lowder, James
    Oganesian, Aram
    Azab, Mohammad
    Garcia-Manero, Guillermo
    [J]. LANCET HAEMATOLOGY, 2019, 6 (04): : E194 - E203
  • [9] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Amrein, Philip C.
    Attar, Eyal C.
    Fathi, Amir Tahmasb
    McAfee, Steven L.
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Foster, Julia
    Stone, Richard M.
    Neuberg, Donna S.
    Ballen, Karen K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
    Simon, Marc A.
    Hanrott, Kate
    Budd, David C.
    Torres, Fernando
    Gruenig, Ekkehard
    Escribano-Subias, Pilar
    Meseguer, Manuel L.
    Halank, Michael
    Opitz, Christian
    Hall, David A.
    Hewens, Deborah
    Powley, William M.
    Siederer, Sarah
    Bayliffe, Andrew
    Lazaar, Aili L.
    Cahn, Anthony
    Rosenkranz, Stephan
    [J]. PULMONARY CIRCULATION, 2022, 12 (01)
12345